SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that it is developing a new tablet formulation to add to its ZEGERID® family of branded prescription pharmaceutical products. The new formulation is a swallowable tablet that combines immediate-release omeprazole, a proton pump inhibitor (PPI), with a mix of buffers. Santarus plans to undertake clinical and stability studies with the tablet in preparation for the submission of a New Drug Application to the U.S. Food and Drug Administration. The company’s objective is to have the new ZEGERID tablet product commercially available in the U.S. in the second half of 2009.
